Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL?

• Earlier this month, Collegium Pharmaceutical issued full-year 2026 earnings guidance, projecting net product revenues between US$805,000,000 and US$825,000,000, giving investors clearer visibility into expected business performance.
• This guidance, released shortly after a very large share price rise in 2025 and insider share sales, adds fresh context to how management views demand for its pain and ADHD treatments.
• Next, we’ll examine how Collegium’s US$805,000,000–US$825,000,000 revenue outlook for 2026 may reshape the company’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Collegium Pharmaceutical Investment Narrative Recap

To own Collegium Pharmaceutical, you need to believe its pain and ADHD brands can sustain meaningful cash generation despite patent cliffs and regulatory scrutiny. The new 2026 revenue guidance of US$805,000,000 to US$825,000,000 mostly reinforces, rather than changes, the near term story, where the key catalyst is execution against this outlook and the biggest risk remains eventual generic pressure on core pain products.

Among recent developments, the late 2025 US$980,000,000 syndicated credit facility stands out in light of this guidance, since it reshapes Collegium’s balance sheet at the same time investors are assessing future cash flows. Together, the new debt structure and 2026 outlook frame how comfortably the company can service interest costs while funding commercialization and potential portfolio moves ahead of upcoming patent expirations.

However, investors should also be aware that future generic competition to its leading pain brands could...

Read the full narrative on Collegium Pharmaceutical (it's free!)

Collegium Pharmaceutical's narrative projects $695.3 million revenue and $131.4 million earnings by 2028. This requires a 0.6% yearly revenue decline and about a $95 million increase in earnings from $36.3 million today.

Uncover how Collegium Pharmaceutical's forecasts yield a $53.17 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$53 to US$240 per share, underlining how far apart views on Collegium can be. When you set that next to the company’s dependence on pain products facing patent expiries, it becomes even more important to compare several independent perspectives before forming a view on future performance.

Explore 3 other fair value estimates on Collegium Pharmaceutical - why the stock might be worth over 5x more than the current price!

Build Your Own Collegium Pharmaceutical Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Collegium Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Collegium Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Collegium Pharmaceutical's overall financial health at a glance.

No Opportunity In Collegium Pharmaceutical?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com